Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF

Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF

Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Onycho-oncology: A Useful Neologism.

Journal of the American Academy of Dermatology·2026

Same author

Mitigating the Increasing Squamous Cell Carcinoma Burden.

Journal of the American Academy of Dermatology·2026

Same author

The wide world of glucagon-like peptide-1 agonist therapy: The thrill of weight loss and the agony of alopecia.

Journal of the American Academy of Dermatology·2026

Same author

Spironolactone rules.

Journal of the American Academy of Dermatology·2026

Same author

Visual recognition and medical dermatology learning needs identified through continuing certification program assessments of the American Board of Dermatology.

Journal of the American Academy of Dermatology·2026

Same author

Mitigating dermatologic malpractice risk: Dueling the sword of Damocles.

Journal of the American Academy of Dermatology·2026

Search research articles

Related Experiment Video

Updated: Dec 20, 2025

Monitoring PD-1-Blocking Antibodies Bound to T Cells Derived from a Drop of Peripheral Blood

Monitoring PD-1-Blocking Antibodies Bound to T Cells Derived from a Drop of Peripheral Blood

Published on: February 5, 2020

Dupilumab cuts both ways

Warren R Heymann¹

¹Cooper Medical School of Rowan University, Marlton, New Jersey.

Journal of the American Academy of Dermatology

|May 22, 2020

Summary

No abstract available in PubMed .

Keywords:

More Related Videos

Author Spotlight: Magnetic Fluorescent Bead-Based Dual-Reporter Flow Analysis of PDL1-Vaxx Peptide Vaccine-Induced Antibody Blockade of the PD-1/PD-L1 Interaction

Author Spotlight: Magnetic Fluorescent Bead-Based Dual-Reporter Flow Analysis of PDL1-Vaxx Peptide Vaccine-Induced Antibody Blockade of the PD-1/PD-L1 Interaction

Published on: July 7, 2023

Murine Model of Epicutaneously-Induced Immunomodulation

Murine Model of Epicutaneously-Induced Immunomodulation

Published on: June 24, 2025

Related Experiment Videos

Last Updated: Dec 20, 2025

Monitoring PD-1-Blocking Antibodies Bound to T Cells Derived from a Drop of Peripheral Blood

Monitoring PD-1-Blocking Antibodies Bound to T Cells Derived from a Drop of Peripheral Blood

Published on: February 5, 2020

Author Spotlight: Magnetic Fluorescent Bead-Based Dual-Reporter Flow Analysis of PDL1-Vaxx Peptide Vaccine-Induced Antibody Blockade of the PD-1/PD-L1 Interaction

Author Spotlight: Magnetic Fluorescent Bead-Based Dual-Reporter Flow Analysis of PDL1-Vaxx Peptide Vaccine-Induced Antibody Blockade of the PD-1/PD-L1 Interaction

Published on: July 7, 2023

Murine Model of Epicutaneously-Induced Immunomodulation

Murine Model of Epicutaneously-Induced Immunomodulation

Published on: June 24, 2025